Targeting CD38 and BCMA in Myeloma: Evidence and Enhanced Outcomes with Innovative Therapies

Stay up-to-date on the latest safety and efficacy data of CD38- and BCMA-targeting therapies being used to treat multiple myeloma while prioritizing patient safety and toxicity management and learn how providers can address disparities in myeloma care, through an expert-written ClinicalThought commentary and a CME-certified on-demand webcast with an accompanying slideset.

Share

Program Content

Activities

CD38 mAbs in NDMM
CD38-Targeted Antibodies in Transplant-Eligible and Transplant-Ineligible Patients With Myeloma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 24, 2024

Expires: July 23, 2025

Managing R/R MM
Antibody–Drug Conjugates, Bispecific Antibodies and CAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 24, 2024

Expires: July 23, 2025

Disparities in MM
Health Disparities in Multiple Myeloma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 24, 2024

Expires: July 23, 2025

Activities

CD38 and BCMA in Multiple Myeloma
Targeting CD38 and BCMA in Myeloma: Evidence and Enhanced Outcomes With Innovative Therapies
Video
Congratulations: You achieved a completion on 04/09/2022

Released: August 09, 2024

Expires: February 08, 2025

Activities

CD38 and BCMA as Targets in Myeloma
Key Insights on CD38 and BCMA as Targets for Therapy in Multiple Myeloma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 28, 2024

Expires: August 27, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Sanofi.

Sanofi